Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis

Abstract Background Anticitrullinated protein antibodies (ACPA) and citrullinated proteins play key roles in the pathogenesis of rheumatoid arthritis (RA). Many candidate citrullinated antigens have been identified in joints, but citrullinated proteins in sera are mostly uncertain in patients with R...

Full description

Bibliographic Details
Main Authors: Hoshimi Kawaguchi, Isao Matsumoto, Atsumu Osada, Izumi Kurata, Hiroshi Ebe, Yuki Tanaka, Asuka Inoue, Naoto Umeda, Yuya Kondo, Hiroto Tsuboi, Yasuhiro Shinkai, Yoshito Kumagai, Akihito Ishigami, Takayuki Sumida
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Arthritis Research & Therapy
Subjects:
PAD
Online Access:http://link.springer.com/article/10.1186/s13075-018-1562-7
id doaj-20feb786dc80465183bc98285a82a06e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Hoshimi Kawaguchi
Isao Matsumoto
Atsumu Osada
Izumi Kurata
Hiroshi Ebe
Yuki Tanaka
Asuka Inoue
Naoto Umeda
Yuya Kondo
Hiroto Tsuboi
Yasuhiro Shinkai
Yoshito Kumagai
Akihito Ishigami
Takayuki Sumida
spellingShingle Hoshimi Kawaguchi
Isao Matsumoto
Atsumu Osada
Izumi Kurata
Hiroshi Ebe
Yuki Tanaka
Asuka Inoue
Naoto Umeda
Yuya Kondo
Hiroto Tsuboi
Yasuhiro Shinkai
Yoshito Kumagai
Akihito Ishigami
Takayuki Sumida
Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
Arthritis Research & Therapy
Rheumatoid arthritis
Citrullinated proteins
Inter-alpha-trypsin inhibitor heavy chain 4
PAD
author_facet Hoshimi Kawaguchi
Isao Matsumoto
Atsumu Osada
Izumi Kurata
Hiroshi Ebe
Yuki Tanaka
Asuka Inoue
Naoto Umeda
Yuya Kondo
Hiroto Tsuboi
Yasuhiro Shinkai
Yoshito Kumagai
Akihito Ishigami
Takayuki Sumida
author_sort Hoshimi Kawaguchi
title Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
title_short Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
title_full Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
title_fullStr Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
title_full_unstemmed Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
title_sort identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis
publisher BMC
series Arthritis Research & Therapy
issn 1478-6362
publishDate 2018-04-01
description Abstract Background Anticitrullinated protein antibodies (ACPA) and citrullinated proteins play key roles in the pathogenesis of rheumatoid arthritis (RA). Many candidate citrullinated antigens have been identified in joints, but citrullinated proteins in sera are mostly uncertain in patients with RA. We explored the expression of citrullinated proteins in joints and sera of experimental arthritis, and we further investigated their specific expression correlated with the disease activity in patients with RA. Methods Citrullinated protein expression in tissues was examined by IHC in peptide glucose-6-phosphate isomerase-induced arthritis (pGIA). Serum citrullinated proteins from pGIA were examined by Western blotting, and the sequence was identified by MS. With the same methods, serum citrullinated proteins were analyzed in patients with RA, primary Sjögren’s syndrome, systemic lupus erythematosus, and osteoarthritis as well as in healthy subjects, by Western blotting and MS. In patients with RA, the relationship between the expression of the identified protein (inter-alpha-trypsin inhibitor heavy chain 4 [ITIH4]) and clinical features was evaluated, and the levels of citrullinated ITIH4 were compared before and after biological treatment. The antibody response against citrullinated ITIH4 peptide was measured by enzyme-linked immunosorbent assay. Results Citrullinated proteins were detected specifically in arthritic joints and sera from pGIA relative to controls. In sera, a common band of citrullinated protein at 120 kDa was revealed, and it fluctuated in parallel with arthritis score of pGIA by Western blotting. Interestingly, in 82% of RA patient sera, similar bands of citrullinated protein were specifically detected. These proteins were identified as citrullinated ITIH4, and especially the R438 site was commonly citrullinated between mice and humans. Citrullinated ITIH4 levels were associated with clinical parameters such as C-reactive protein (CRP), rheumatoid factor, and Disease Activity Score in 28 joints as measured by CRP in patients with RA. Its levels were decreased in correlation with the reduction of disease activity score after effective treatment in patients with RA. Moreover, antibody response to citrullinated epitope in ITIH4 was specifically observed in patients with RA. Conclusions Our results suggest that serum citrullinated ITIH4 was specifically increased in patients with RA and could be a novel biomarker for assessing disease activity in patients with RA.
topic Rheumatoid arthritis
Citrullinated proteins
Inter-alpha-trypsin inhibitor heavy chain 4
PAD
url http://link.springer.com/article/10.1186/s13075-018-1562-7
work_keys_str_mv AT hoshimikawaguchi identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT isaomatsumoto identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT atsumuosada identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT izumikurata identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT hiroshiebe identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT yukitanaka identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT asukainoue identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT naotoumeda identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT yuyakondo identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT hirototsuboi identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT yasuhiroshinkai identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT yoshitokumagai identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT akihitoishigami identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
AT takayukisumida identificationofnovelbiomarkerascitrullinatedinteralphatrypsininhibitorheavychain4specificallyincreasedinserawithexperimentalandrheumatoidarthritis
_version_ 1716788387998859264
spelling doaj-20feb786dc80465183bc98285a82a06e2020-11-24T20:57:14ZengBMCArthritis Research & Therapy1478-63622018-04-0120111310.1186/s13075-018-1562-7Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritisHoshimi Kawaguchi0Isao Matsumoto1Atsumu Osada2Izumi Kurata3Hiroshi Ebe4Yuki Tanaka5Asuka Inoue6Naoto Umeda7Yuya Kondo8Hiroto Tsuboi9Yasuhiro Shinkai10Yoshito Kumagai11Akihito Ishigami12Takayuki Sumida13Department of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaEnvironmental Biology Laboratory, Faculty of Medicine, University of TsukubaEnvironmental Biology Laboratory, Faculty of Medicine, University of TsukubaMolecular Regulation of Aging, Tokyo Metropolitan Institute of GerontologyDepartment of Internal Medicine, Faculty of Medicine, University of TsukubaAbstract Background Anticitrullinated protein antibodies (ACPA) and citrullinated proteins play key roles in the pathogenesis of rheumatoid arthritis (RA). Many candidate citrullinated antigens have been identified in joints, but citrullinated proteins in sera are mostly uncertain in patients with RA. We explored the expression of citrullinated proteins in joints and sera of experimental arthritis, and we further investigated their specific expression correlated with the disease activity in patients with RA. Methods Citrullinated protein expression in tissues was examined by IHC in peptide glucose-6-phosphate isomerase-induced arthritis (pGIA). Serum citrullinated proteins from pGIA were examined by Western blotting, and the sequence was identified by MS. With the same methods, serum citrullinated proteins were analyzed in patients with RA, primary Sjögren’s syndrome, systemic lupus erythematosus, and osteoarthritis as well as in healthy subjects, by Western blotting and MS. In patients with RA, the relationship between the expression of the identified protein (inter-alpha-trypsin inhibitor heavy chain 4 [ITIH4]) and clinical features was evaluated, and the levels of citrullinated ITIH4 were compared before and after biological treatment. The antibody response against citrullinated ITIH4 peptide was measured by enzyme-linked immunosorbent assay. Results Citrullinated proteins were detected specifically in arthritic joints and sera from pGIA relative to controls. In sera, a common band of citrullinated protein at 120 kDa was revealed, and it fluctuated in parallel with arthritis score of pGIA by Western blotting. Interestingly, in 82% of RA patient sera, similar bands of citrullinated protein were specifically detected. These proteins were identified as citrullinated ITIH4, and especially the R438 site was commonly citrullinated between mice and humans. Citrullinated ITIH4 levels were associated with clinical parameters such as C-reactive protein (CRP), rheumatoid factor, and Disease Activity Score in 28 joints as measured by CRP in patients with RA. Its levels were decreased in correlation with the reduction of disease activity score after effective treatment in patients with RA. Moreover, antibody response to citrullinated epitope in ITIH4 was specifically observed in patients with RA. Conclusions Our results suggest that serum citrullinated ITIH4 was specifically increased in patients with RA and could be a novel biomarker for assessing disease activity in patients with RA.http://link.springer.com/article/10.1186/s13075-018-1562-7Rheumatoid arthritisCitrullinated proteinsInter-alpha-trypsin inhibitor heavy chain 4PAD